Spikevax Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The spikevax market research report is one of a series of new reports that provides spikevax market statistics, including the spikevax industry's global market size, regional shares, competitors with a spikevax market share, detailed spikevax market segments, market trends and opportunities, and any further data you may need to thrive in the spikevax industry. This spikevax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising booster shot campaigns, emergence of new SARS-CoV-2 variants, rising government contracts for pandemic preparedness, increasing vaccination rates in developing countries, expansion into pediatric and adolescent populations, and rising regulatory approvals for variant-specific formulations. Major trends in the forecast period include development of bivalent vaccines targeting multiple COVID-19 variants, advancements in storage system, enhanced mRNA technology for faster production, and integration of digital tools for vaccine tracking and monitoring.

The increasing prevalence of COVID-19 cases is expected to drive growth in the Spikevax market. COVID-19, caused by the SARS-CoV-2 virus, spreads through respiratory droplets and leads to a range of symptoms from mild fever to severe respiratory distress. While vaccines and hygiene practices help curb transmission, the number of cases continues to rise due to factors such as new variants, waning immunity, relaxed restrictions, seasonal indoor gatherings, and uneven vaccine distribution. Spikevax works by training the immune system to recognize and combat the virus through an mRNA-induced spike protein, providing robust protection against severe illness and variants. For instance, in March 2023, the Office for National Statistics reported that around 1.9 million people in the UK (2.9% of the population) were experiencing long COVID, with most having had COVID-19 over 12 weeks earlier. With 69% still suffering symptoms for more than a year and 41% for over two years, the growing number of COVID-19 cases is set to drive the Spikevax market forward.

The increasing investment in healthcare is also expected to support the growth of the Spikevax market. Healthcare investments include expenditures on medical services, treatments, medications, and hospital care, which are rising due to factors such as an aging population, higher healthcare demands, technological advancements, and escalating prices for services and drugs. These investments drive the adoption of Spikevax by funding vaccine procurement, enhancing healthcare infrastructure, and improving distribution systems, thereby ensuring wider access to the vaccine and supporting public health initiatives. For instance, the Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a significant rise compared to the 0.9% growth in 2022. The growing healthcare investment is expected to propel the growth of the Spikevax market.

In February 2022, Moderna partnered with Thermo Fisher Scientific to expand the U.S.-based production of Spikevax and other mRNA-based therapies. Thermo Fisher’s advanced manufacturing capabilities align with Moderna’s goals to scale up production and advance its mRNA technology platform. Thermo Fisher, a leading biotechnology company in the U.S., specializes in developing and manufacturing transformative therapies, including mRNA medicines, which will further enhance the availability and distribution of Spikevax in the U.S. market.

The key company operating in the spikevax market is Moderna Inc.

North America was the largest region in the spikevax market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spikevax report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spikevax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Spikevax is a vaccine designed to prevent coronavirus disease 2019 (COVID-19) in individuals aged 6 months and older. It was developed using an active ingredient called elasomeran, a messenger RNA (mRNA) molecule that provides genetic instructions for cells to produce a spike protein from the original SARS-CoV-2 strain. This process helps the immune system recognize and fight the virus.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indication for spikevax is COVID-19, a viral respiratory illness caused by the SARS-CoV-2 virus. COVID-19 presents symptoms such as fever, cough, and breathing difficulties. Spikevax, an mRNA-based vaccine, works by instructing the body’s cells to produce a protein similar to the spike protein on the virus’s surface. This allows the immune system to identify and respond to the virus if it enters the body. Various formulations of Spikevax are available, including Spikevax Original, Spikevax Bivalent (original or Omicron), and Spikevax XBB.1.5. It is distributed through government channels, hospitals, and clinics, and is used by a wide range of age groups, including adults, adolescents, and children.

The spikevax market consists of sales of COVID-19 vaccines, bivalent booster vaccines, syringes, and needles. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

The market value is defined as the revenues generated from the sale of vaccines and services within the market and geography, expressed in USD unless specified otherwise. These revenues represent consumption values based on vaccines used or distributed in a specific region, regardless of their place of production.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.